Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 92DJ3 | — |
31-year-old patient received a pediatric dose of Engerix B; underdose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 31-year-old male patient who received HBV (Engerix B pediatric) (batch number 92DJ3, expiry date 03-MAY-2025) for prophylaxis. On 16-JAN-2025, the patient received the 3rd dose of Engerix B pediatric. On 16-JAN-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: 31-year-old patient received a pediatric dose of Engerix B) and underdose (Verbatim: underdose). The outcome of the adult use of a child product and underdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-JAN-2025 Vaccine Coordinator stated a 31-year-old patient received a pediatric dose of Engerix-B, which led to adult use of a child product and underdose.